An in silico—in vitro Pipeline Identifying an HLA-A(*)02:01(+) KRAS G12V(+) Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

Targeting CD8(+) T cells to recurrent tumor-specific mutations can profoundly contribute to cancer treatment. Some of these mutations are potential tumor antigens although they can be displayed by non-spliced epitopes only in a few patients, because of the low affinity of the mutated non-spliced pep...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishto, Michele, Mansurkhodzhaev, Artem, Ying, Ge, Bitra, Aruna, Cordfunke, Robert A., Henze, Sarah, Paul, Debdas, Sidney, John, Urlaub, Henning, Neefjes, Jacques, Sette, Alessandro, Zajonc, Dirk M., Liepe, Juliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872521/
https://www.ncbi.nlm.nih.gov/pubmed/31803176
http://dx.doi.org/10.3389/fimmu.2019.02572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872521/
https://www.ncbi.nlm.nih.gov/pubmed/31803176
http://dx.doi.org/10.3389/fimmu.2019.02572

Ejemplares similares